Two days post last treatment of ALX148, a significant increase in tumor infiltrating CD8+ (p<0.0001) and CD4+ T cells (p<0.0001) (Fig 9B and 9C) was seen in mice receiving combination treatment compared to vehicle control. Here, CD8A is linked to neoplasm.